Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepodisiran in Participants With Normal Hepatic Function and Hepatic Impairment
NCT06916078Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Countries
- 2
01
Overview
Phase 1, open-label trial of lepodisiran in elevated lipoprotein(a) (Lp(a)) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve of Lepodisiran and Maximum Concentration of Lepodisiran. Started Apr 2025; status: completed.
02
Drugs
lepodisiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT06916078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916078.